- Previous Close
464.85 - Open
469.90 - Bid --
- Ask --
- Day's Range
465.10 - 479.00 - 52 Week Range
314.00 - 519.50 - Volume
333,146 - Avg. Volume
321,074 - Market Cap (intraday)
65.17B - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
124.02 - EPS (TTM)
3.77 - Earnings Date Feb 6, 2025 - Feb 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
328.33
HealthCare Global Enterprises Limited, together with its subsidiaries, provides medical and healthcare services focusing on cancer and fertility in India and internationally. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates multi-specialty hospitals under the HCG brand that provides inpatient and outpatients treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. In addition, the company offers cancer diagnostic services; combining laboratory services; and research and development, and clinical research to enhance cancer diagnosis and prognosis. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
www.hcgoncology.com6,150
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: HCG.NS
View More
Performance Overview: HCG.NS
Trailing total returns as of 11/12/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HCG.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HCG.NS
View MoreValuation Measures
Market Cap
64.79B
Enterprise Value
74.81B
Trailing P/E
123.96
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.31
Price/Book (mrq)
7.85
Enterprise Value/Revenue
3.96
Enterprise Value/EBITDA
21.90
Financial Highlights
Profitability and Income Statement
Profit Margin
2.66%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
19.77B
Net Income Avi to Common (ttm)
526.1M
Diluted EPS (ttm)
3.77
Balance Sheet and Cash Flow
Total Cash (mrq)
3.03B
Total Debt/Equity (mrq)
147.31%
Levered Free Cash Flow (ttm)
--
Research Analysis: HCG.NS
View MoreCompany Insights: HCG.NS
HCG.NS does not have Company Insights